Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 38%
Hold 23%
Sell 8%
Strong Sell 0%

Bulls say

Icon is poised for strong growth with positive bookings, a strong focus on larger and more stable clients, and a solid financial position with planned debt payments. Management's confidence in continued earnings improvement and potential guidance raise bodes well for the company's future success. The company's global reach and diverse range of services make it a strong player in the contract research organization market, and its partnerships with life sciences firms provide a strong foundation for continued growth and success.

Bears say

Icon is facing intense competition in the CRO market, and its cancellation levels and direct-fee revenue remain unchanged despite strong commercial performance and higher than expected passthrough revenue. Additionally, the company's 2Q26 results reflect a decline in direct-fee revenue and an increase in passthrough revenue, which could impact future reported revenue and margins. Furthermore, while the company sets ambitious sustainability targets, its materiality assessment identifies access to clinical trials, diversity and inclusion, and climate change as key priorities, indicating potential challenges in these areas.

ICON (ICLR) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 38% recommend Buy, 23% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 13 analysts, ICON (ICLR) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $181.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $181.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.